-The Information Report
Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $27
Morgan Stanley analyst Matthew Harrison maintains AlloVir (NASDAQ:ALVR) with a Overweight and lowers the price target from $32 to $27.
Related Posts
US Stocks Could Pause For Breather After 2-Session Rally As Futures Slump; Twitter, Tesla, Ford On Investor Radar
Futures trading indicates that the two-day rally seen in the market may stall, as traders pause for a breather and harp on economic fundamentals.
On Tuesday, the major U.S. averages gap-opened sharply higher. Consolidating the gains over the course of the sessions, each of them closed 2.8% or above.
‘Putin Grants Citizenship To Edward Snowden, Who Disclosed U.S. Surveillance’ – Washington Post
https://www.washingtonpost.com/world/2022/09/26/putin-snowden-citizenship-russia/
Russian President Vladimir Putin granted citizenship on Monday to Edward Snowden, the former security consultant who leaked information
Why Jaguar Health Stock Is Up Today
Jaguar Health shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group. The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is for the treatment of oral mucositis, also called "chemo mouth." "We are very happy to have executed the in-license agreement for Gelclair - and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO.